Male Sex Hormones Drug Sildenafil Citrate Male Enhancement Steroids White Powder

Sildenafil Infor

Chemical name: Sildenafil (Viagra) (Steroids)
CAS: 139755-83-2
Assay: 99% min.
Molecular formula: C22H30N6O4S
Molecular weight: 474.58
Packing: 1kg net/foil bag, 5kg/drum.
Delivery: Express courier.
Character: White or almost white crystalline powder, odorless, bitter astringent taste, insoluble in water and ethanol.

Sildenafil Description:

Sildenafil, sold as Viagra and other trade names, is a medication used to treat erectile dysfunctionandpulmonary arterial hypertension. Its effectiveness for treating sexual dysfunction in women has not been demonstrated.

Sildenafil relaxes muscles found in the walls of blood vessels and increases blood flow to particular areas of the body.

Sildenafil under the name Viagra is used to treat erectile dysfunction (impotence) in men.

Another brand of sildenafil is Revatio, which is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women.

Sildenafil Application:

Sildenafil citrate, sold as Viagra, Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was originally discovered by Pfizer scientists Andrew Bell, David Brown, and Nicholas Terrett.

The primary indication of sildenafil is treatment of erectile dysfunction (inability to sustain a satisfactory erection to complete intercourse). Its use is now standard treatment for erectile dysfunction in all settings, including diabetes.

In clinical trials, the most common adverse effects of sildenafil use included headache, flushing, dyspepsia, nasal congestion and impaired vision, including photophobia and blurred vision.Some sildenafil users have complained of seeing everything tinted blue (cyanopsia).Some complained of blurriness and loss of peripheral vision. In July 2005, the FDA found that sildenafil could lead to vision impairment in rare cases and a number of studies have linked sildenafil use with nonarteritic anterior ischemic optic neuropathy.

Rare but serious adverse effects found through postmarketing surveillance include priapism, severe hypotension, myocardial infarction (heart attack), ventricular arrhythmias, stroke, increased intraocular pressure, and sudden hearing loss. As a result of these postmarketing reports, in October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including sildenafil, required a more prominent warning of the potential risk of sudden hearing loss.